Mylan Files Lawsuit Against Pittsburgh Post-Gazette
PITTSBURGH, Aug. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL)
today announced that the company and its subsidiary Mylan Pharmaceuticals Inc.
filed a civil lawsuit in the Circuit Court of Monongalia County, W.Va.,
against the Pittsburgh Post-Gazette, Post-Gazette reporters Len Boselovic and
Patricia Sabatini, and others as yet unknown.
The lawsuit was filed after the newspaper published a series of
sensational and misleading articles based on improperly obtained and
misconstrued confidential internal documents. The articles mischaracterized a
minor deviation from an internal Mylan procedure, creating the false
appearance of significant quality and regulatory issues at Mylan's Morgantown,
W.Va., plant when no such issues existed. The U.S. Food and Drug
Administration (FDA) recently concluded a review at the facility and
determined that there were no deficiencies and that no action was required.
The lawsuit seeks, among other things, the return of the internal
confidential and proprietary documents in the Post-Gazette's possession that
were improperly obtained without Mylan's knowledge or consent. The lawsuit
challenges what the Post-Gazette has described as proper news-gathering
techniques as well as the improper distribution of Mylan's internal documents
to others who then reviewed them without the complete set of facts. This
contributed to the noted mischaracterizations and misleading allegations in
the numerous articles published on this matter.
In addition to recovery of its internal documents, Mylan also seeks to
recover compensatory, exemplary and other appropriate relief from the named
defendants and any others, as yet unknown, who were involved in or possibly
benefitted from the wrongful conduct.
Mylan Chairman and CEO Robert J. Coury said: "We are very disappointed
that this situation occurred and reached this level, however, we have no other
alternative but to address this type of misconduct. This matter has now been
turned over to Mylan's legal department, and as consistent with our long-time
policy not to comment on litigation, we will not be discussing this matter
going forward. Mylan's management team will continue to maintain its
unwavering focus on executing and delivering on its long-standing objectives."
Mylan Inc., which provides products to customers in more than 140
countries and territories, ranks among the leading diversified generic and
specialty pharmaceutical companies in the world. The company maintains one of
the industry's broadest - and highest quality - product portfolios, supported
by a robust product pipeline; owns a controlling interest in the world's third
largest active pharmaceutical ingredient manufacturer; and operates a
specialty business focused on respiratory and allergy therapies. For more
information, please visit www.mylan.com.
SOURCE Mylan Inc.
CONTACT: Media, Michael Laffin, +1-724-514-1968; or Investors, Dan
Crookshank, +1-724-514-1813, both of Mylan Inc.
Close window | Back to top